28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00807872 (ClinicalTrials.gov) | December 2008 | 11/12/2008 | Radioimmunoimaging of AL Amyloidosis | Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4 | Primary Amyloidosis | Biological: 124I-labeled monoclonal antibody Mu 11-1F4 | University of Tennessee | FDA Office of Orphan Products Development | Completed | 21 Years | 90 Years | Both | 40 | Phase 1 | United States |
2 | NCT01409148 (ClinicalTrials.gov) | November 2008 | 28/7/2011 | Radioimmunoimaging of AL Amyloidosis | Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody Mu 11-1F4 | AL Amyloidosis | Biological: 124I-labeled monoclonal antibody Mu 11-1F4 | University of Tennessee | Food and Drug Administration (FDA) | Completed | 21 Years | 90 Years | Both | 38 | Phase 1 | United States |